Supplementary Materials

Supplementary Material for:

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Annika S. Axelsson, Emily Tubbs, Brig Mecham, Shaji Chacko, Hannah A. Nenonen, Yunzhao Tang, Jed W. Fahey, Jonathan M. J. Derry, Claes B. Wollheim, Nils Wierup, Morey W. Haymond, Stephen H. Friend, Hindrik Mulder, Anders H. Rosengren*

*Corresponding author. Email: anders.rosengren{at}gu.se

Published 14 June 2017, Sci. Transl. Med. 9, eaah4477 (2017)
DOI: 10.1126/scitranslmed.aah4477

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Effect of SFN on apoptosis, insulin signaling, and OCR in H4IIE cells.
  • Fig. S2. Effect of SFN on the 50-gene hepatic disease signature.
  • Fig. S3. Effect of BSE on H4IIE cells and on mice fed an HFD.
  • Table S1. The 50-gene liver disease signature for T2D.
  • Legends for tables S2 and S3
  • Table S4. Expression of enzymes involved in gluconeogenesis.
  • Table S5. Adverse effects in patients treated with BSE or placebo for 12 weeks.
  • Table S6. Characteristics of patients discontinuing the study.
  • References (6169)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2. List of compounds used in the analysis (see separate Excel file).
  • Table S3. Rank order of compounds (see separate Excel file).

Download Tables S2 and S3